Photo: Pixabay
THE recent declaration by Asean member states to bolster regional drug security, particularly under the Asean Drug Security and Self-Reliance (ADSSR) initiative, is a significant and commendable step forward.
This commitment, adopted during the 46th Asean Summit under Malaysia’s 2025 Chairmanship, resonates deeply with the Malaysian pharmaceutical industry, which is well equipped to contribute significantly to this regional aspiration, particularly through its strength in high-quality generics and biosimilars manufacturing.
